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ABSTRACT
Background In patients with a minor ischaemic stroke 
or transient ischaemic attack (TIA), separate trials have 
shown that dual antiplatelet therapy with clopidogrel plus 
aspirin (clopidogrel–aspirin) or ticagrelor plus aspirin 
(ticagrelor–aspirin) are more effective than aspirin alone 
in stroke secondary prevention. However, these two sets 
of combination have not been directly compared. Since 
clopidogrel was less effective in stroke patients who were 
CYP2C19 loss- of- function (LOF) allele carriers, whether 
ticagrelor–aspirin is clinically superior to clopidogrel–
aspirin in this subgroup of patients with stroke is unclear.
Aim To describe the rationale and design considerations 
of the Clopidogrel in High- risk patients with Acute Non- 
disabling Cerebrovascular Events (CHANCE-2) trial.
Design CHANCE-2 is a randomised, double- blind, double- 
dummy, placebo- controlled, multicentre trial that compares 
two dual antiplatelet strategies for minor stroke or TIA 
patients who are CYP2C19 LOF allele carriers: ticagrelor 
(180 mg loading dose on day 1 followed by 90 mg twice 
daily on days 2–90) or clopidogrel (300 mg loading dose on 
day 1 followed by 75 mg daily on days 2–90), plus open- 
label aspirin with a dose of 75–300 mg on day 1 followed 
by 75 mg daily on day 2–21. All will be followed for 1 year.
Study outcomes The primary efficacy outcome is any 
stroke (ischaemic or haemorrhagic) within 3 months and 
the primary safety outcome is any severe or moderate 
bleeding event within 3 months.
Discussion The CHANCE-2 trial will evaluate whether 
ticagrelor–aspirin is superior to clopidogrel–aspirin for 
minor stroke or TIA patients who are CYP2C19 LOF allele 
carriers.
Trial registration number NCT04078737.
INTRODUCTION AND RATIONALE
In patients with acute non- disabling cerebro-
vascular events, including those with acute 
minor stroke or transient ischaemic attack 
(TIA), the subsequent recurrent stroke and 
cardiovascular events are more than 6% in 
the first year.1 2 As shown in Clopidogrel in 
High- risk patients with Acute Non- disabling 
Cerebrovascular Events (CHANCE) trial and 
the Platelet- Oriented Inhibition in New TIA 
and Minor Ischaemic Stroke (POINT) trial, a 
lower risk of stroke recurrence was observed 
with a combination of clopidogrel and aspirin 
(clopidogrel–aspirin) than with aspirin 
alone.3 4 However, the choice of an optimal 
dual antiplatelet therapy regimen for patients 
with strokes requires a tailored approach 
based on the characteristics of the patient. 
The genetic substudy of the CHANCE trial 
showed that clopidogrel plus aspirin reduced 
the risk of stroke recurrence in non- carriers 
of the cytochrome P450 2C19 (CYP2C19) 
loss- of- function (LOF) alleles compared 
with aspirin alone but not in carriers. There-
fore, clopidogrel may not provide additional 
benefit in stroke prevention compared with 
aspirin alone for the carriers.5 More recently, 
the substudy of POINT failed to reproduce 
the above findings as seen in the CHANCE 
trial, possibly from a limited statistical power.6 
In addition, a meta- analysis of 15 studies that 
included 4762 patients with stroke or TIA 
found that carriers of CYP2C19 LOF alleles 
were at higher risk of vascular events than 
non- carriers when taking clopidogrel.7
Ticagrelor is a reversible oral antago-
nist directly blocking the P2Y12- adenosine 
diphosphate receptor that needs no catab-
olite activation, which in turn yields greater 
mean levels of platelet inhibition than clopi-
dogrel.8 9 From the Acute Stroke or Tran-
sient Ischaemic Attack Treated with Aspirin 
or Ticagrelor and Patient Outcomes trial 
involving participants with acute ischaemic 
stroke or TIA, ticagrelor was not found to 
be more effective than aspirin in reducing 
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the risk of 90- day vascular events.5 However, among 
the Asian patients, a tendency towards better efficacy 
was seen in a subgroup analysis.10 The Platelet Reac-
tivity in Acute Stroke or Transient Ischaemic Attack 
trial showed that participants with ischaemic stroke or 
TIA who were treated with ticagrelor plus aspirin (tica-
grelor–aspirin) had a lower proportion of high platelet 
reactivity than those who were treated with clopidogrel–
aspirin, particularly in the those who were CYP2C19 LOF 
allele carriers.11 The Acute Stroke or Transient Isch-
aemic Attack Treated with Ticagrelor and Aspirin for 
Prevention of Stroke and Death trial showed that dual 
antiplatelet therapy (ticagrelor–aspirin) was better than 
mono antiplatelet therapy (aspirin) for secondary stroke 
prevention in people with mild- to- moderate acute isch-
aemic stroke or TIA, but the rate of haemorrhage was 
also elevated.12
While separate trials have shown similar treatment 
effects, no direct comparison has been conducted in this 
patient population. In some populations, more than 50% 
of them carry CYP2C19 LOF alleles so that the conver-
sion to an active form of clopidogrel is reduced. We 
hence hypothesised that, compared with clopidogrel–
aspirin, ticagrelor–aspirin may favourably impact the 
clinical outcomes in high- risk participants with acute non- 
disabling cerebrovascular events and were carriers of the 
CYP2C19 LOF allele. Therefore, the CHANCE-2 trial was 
designed to test such hypothesis. The intention of this trial 
is to evaluate the safety and efficacy of ticagrelor–aspirin 
versus clopidogrel–aspirin for minor stroke or high- risk 
TIA patients who were CYP2C19 LOF allele carriers. This 
article describes the design of the CHANCE-2 trial and is 
a summary of protocol.
METHODS
Design and patients population
CHANCE-2 is a randomised, double- blind, double- 
dummy, placebo- controlled multicentre trial. Patients 
with CYP2C19 LOF alleles are randomised with 1:1 to 
one of the two strategies (ticagrelor–aspirin or clopi-
dogrel–aspirin) within 24 hours of the onset of cere-
brovascular Events. All participants will be followed 
for 3 months on study intervention, with another 9 
months of follow- up on standard of care. The study 
design of the CHANCE-2 is shown in figure 1. The 
trial will enrol subjects age ≥40 years with acute non- 
disabling ischaemic stroke, with a National Institutes 
of Health Stroke Scale (NIHSS) score ≤3 or high- risk 
TIAs (ABCD2 score ≥4). Once randomised, they will be 
treated with study drug within 24 hours of symptoms 
onset. Figure 2 lists the summary of inclusion and exclu-
sion criteria. Prior to initiating the study, each clinical 
site obtains institutional review board (IRB) approval 
for the protocol, informed consent, and materials used 
to recruit subjects. Participants from 240 hospitals in 
China will be enrolled in CHANCE-2.
Genotyping
In this study, a novel point- of- care genetic test platform 
will be used to identify carriers of CYP2C19 LOF alleles 
including poor metabolisers with at least two *2 or *3 
alleles (*2/*2, *2/*3, or *3/*3) or intermediate metab-
olisers with one *2 or *3 allele (*1/*2 or *1/*3). The 
CYP2C19 genotyping will be implemented by the GMEX 
Point- of- Care Genotyping system, including a portable 
DNA analyser, genotyping reagents, and a buccal sample 
collection kit. The system uses non- invasive sampling 
by buccal swab and integrates automated steps of DNA 
extraction, PCR- based amplification, fluorescent signal 
detection and genotype determination. The system inte-
grates controls to monitor the performance of a run 
and ensure ongoing quality from the GMEX system. 
The analysis includes the single nucleotide polymor-
phisms CYP2C19*2 (681G>A, rs4244285), CYP2C19*3 
(636G>A, rs4986893), and CYP2C19*17 (−806C>T, 
rs12248560), which will be genotyped on screening. 
The average result turn- around- time for the method of 
GMEX is 85 min.13
Randomisation
Participants will be randomised (1:1) to receive either 
ticagrelor–aspirin or clopidogrel–aspirin. A randomisa-
tion sequence will be generated centrally using random- 
permuted fixed- size blocks methods from the Statistics 
and Data Centre at the China National Clinical Research 
Centre for Neurological Diseases. The randomisation 
computer program makes the treatment assignment 
based on the current status of treatment group distribu-
tion within each clinical centre as well as overall balance 
of treatment assignment. Following randomised alloca-
tion, the study intervention will be administered to the 
patient as early as possible.
Intervention
Eligible participants are randomly assigned to one of two 
arms:
Ticagrelor–aspirin group
A 180 mg loading dose of Ticagrelor on day 1, followed 
by 90 mg two times per day on days 2–90 plus a 75–300 
mg loading dose of aspirin, followed by 75 mg daily for 
21 days;
Clopidogrel–aspirin group
A 300 mg loading dose of clopidogrel on day 1, followed 
by 75 two times per day on days 2–90 plus a 75–300 mg 
loading dose of aspirin followed by 75 mg daily for 21 
days.
Patient will take the first dose of the study drug on the 
first visit. Then, for the next 12 weeks, the study drug 
should be taken twice daily, 12 hours apart. Once the study 
period is over at the end of 12th week, the treating physi-
cian will decide what antiplatelet drug to be continued. 
All participants will be followed for 1 year.
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Figure 1 CHANCE-2 study design. CHANCE-2, Clopidogrel in High- risk patients with Acute Non- disabling Cerebrovascular 
Events; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischaemic attack；ASA，aspirin; ULN, upper limit of 
normal; ALT, alanine aminotransferase; AST，aspartate transaminase；AV, atrioventricular.
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Primary outcomes
The primary efficacy outcome is any stroke (ischaemic or 
haemorrhagic) within 3 months. Definitions of stroke are 
provided in online supplemental table 1.
Secondary outcomes
Secondary outcomes include the following events: (1) 
Any new stroke events within 30 days and 1 year; (2) New 
clinical vascular events including stroke, TIA, myocardial 
infarction and vascular deaths within 3 months and 1 
year ; (3) New ischaemic stroke within 3 months and 1 
year; (4) Disabling stroke (Modified Rankin Scale score, 
mRS >1) at 3 months and 1 year; (5) Incidence and 
severity of recurrent stroke and TIA during follow- up to 3 
months and 1 year. Severity is measured using a six- level 
ordered categorical scale that incorporates the mRS: fatal 
stroke/severe non- fatal stroke (mRS 4 or 5)/moderate 
stroke (mRS 2 or 3)/mild stroke (mRS 0 or 1)/TIA/no 
stroke- TIA; (6) Neurological impairment at 3 months 
(NIHSS increased ≥4 from baseline); (7) Quality of Life 
(EuroQol-5dimension) scale. The influence on treatment 
effect of age, gender, body mass index, index event type 
(TIA vs minor stroke), time from index event to randomi-
sation, aetiology subtype, diabetes mellitus, hypertension, 
type of LOF allele, previous ischaemic stroke or TIA, prior 
antiplatelet therapy, prior statin therapy, prior smoking 
status and symptomatic intracranial and extracranial 
artery stenosis will be evaluated in subgroup analyses.
Safety outcomes
The primary safety outcome is severe or moderate 
bleeding event within 3 months. The bleeding event is 
defined by the criteria from the Global Utilisation of Strep-
tokinase and Tissue Plasminogen Activator for Occluded 
Coronary Arteries (GUSTO) trial.14 Severe haemorrhage 
is defined as fatal or intracranial haemorrhage or other 
haemorrhage causing haemodynamic compromise that 
requires blood or fluid replacement, inotropic support or 
surgical intervention. Moderate haemorrhage is defined 
as bleeding that required transfusion of blood but does 
not lead to haemodynamic compromise requiring inter-
vention. Other secondary safety outcomes include the 
following events within a 3- month and 1- year time frame: 
(1) Incidence of severe bleedings or moderate bleed-
ings (GUSTO definition) at 1 year; (2) Bleeding events; 
(3) Mortality; (4) Adverse events (AEs)/serious adverse 
events (SAEs) reported by the investigators.
Data safety and monitoring board
To ensure ethically conduct of the trial and patient 
safety, the data safety and monitoring board (DSMB) will 
meet per protocol and monitor the progress of the trial. 
Members of DSMB do not participate in the trial and 
their responsibilities are defined by the trial Executive 
Committee prior to the beginning of the trial. DSMB will 
provide their recommendations in written statement to 
the Chairs of trial Steering Committee after each meeting.
Sample size
The sample size calculation is based on the rate of the 
primary outcome (3- month risk of stroke) and estimated 
effect size. We used the following assumptions: (1) Signif-
icance level of 0.048 for a two- sided test; (2) Statistical 
power of 90%; (3) 3- month rate of stroke event is 9.4% in 
control group based on the data from the CHANCE trial5; 
(4) Proportional risk reduction of 25% (Rate ratio=0.75); 
(5) of 5% over 3 months. We estimated that 6396 eligible 
patients (3198 for each treatment group) are required. 
As 58.8% of patients are CYP2C19 LOF allele carriers,5 we 
need to screen about 10 878 patients in total.
Interim analysis
The interim analysis will focus on patient recruitment, 
baseline comparability of treatment arms, sample sizes 
with regard to event rates, loss to follow- up, adverse effects 
data and effect of treatment on the primary endpoints. We 
plan one interim analysis when 60% of total patients have 
undergone randomisation and completed the follow- up. 
The sample size is inflated to account for one interim 
analysis of the primary efficacy outcome with the use of 
an O’Brien- Fleming spending function, and a p<0.008 is 
considered to be statistically significant during the interim 
analysis. In the final analysis, a p<0.048 is considered to be 
statistically significant in the current study. Trial investiga-
tors will be blinded to the interim outcome results.
Statistical analyses
An intention- to- treat analysis will be used for all partici-
pants randomised to an intervention group. Participants 
will be censored at their last follow- up assessment when 
experiencing a clinical event, at the end of study, or at 
the time of withdrawal from the study. Statistically, the 
cumulative risk of any ischaemic or haemorrhagic event 
will be reported as a Kaplan- Meier estimates during the 
90- day follow- up. Cox proportional hazards methods will 
be used for HR calculation at 95% CIs. The treatment 
effect will be assessed by the log- rank test. This approach 
is to maximise the time- dependent information in the 
trial while still acknowledge the ease of interpretation of 
Figure 2 Summary of inclusion and exclusion criteria. 
HR- NICE, high- risk patients with acute non- disabling 
cerebrovascular events (TIA or acute minor stroke); LOF, loss- 
of- function.
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risks. Accounting for a single interim analysis, a p value of 
0.048 will be considered to indicate statistical significance 
for the primary outcome. Detailed analysis plans will be 
given in the statistical analysis plan before the database is 
locked and the blind is broken.
Study organisation
The Trial Steering Committee provides oversight and stra-
tegic input and will meet twice yearly. The Trial Manage-
ment Committee runs the trial on a day- to- day basis and 
is based at the CHANCE-2 Trial Coordinating Centre of 
the China National Clinical Research Centre for Neuro-
logical Diseases. Outcomes, SAEs, and brain imaging are 
adjudicated by trained assessors masked to treatment 
assignment.
DISCUSSION
CHANCE-2 will address a major issue in secondary 
prevention in those TIA or minor stroke patients who are 
CYP2C19 LOF allele carriers. Furthermore, the safety and 
efficacy of ticagrelor–aspirin or clopidogrel–aspirin will 
be assessed.
Two recent RCTs revealed that the short term clopi-
dogrel–aspirin therapy is beneficial after acute minor 
stroke or TIA.3 4 However, several studies have showed 
the higher risk of poor clinical outcomes in CYP2C19 
LOF allele carriers who receiving clopidogrel.15–18 A 
genetic substudy of the Secondary Prevention of Small 
Subcortical Strokes trial reported that patients with one 
CYP2C19 LoF allele carriers had higher odds of stroke 
recurrence compared with non- carriers.19 A preplanned 
substudy of the CHANCE trial found that CYP2C19 LoF 
carriers had 1.5 times the risk of recurrent stroke as non- 
carriers at 90 days.5 To date, there is no evidence from 
randomised trials for a direct comparison of treatment 
effect between ticagrelor and clopidogrel with aspirin 
added on for secondary stroke prevention. Clopidogrel–
aspirin is still the approved option for secondary stroke 
prevention in patients with acute non- disabling cerebro-
vascular events.20
SUMMARY AND CONCLUSIONS
The CHANCE-2 trial will produce reliable data on 
whether ticagrelor–aspirin is superior to the recommen-
dations from current guidelines, clopidogrel–aspirin, for 
the prevention of recurrent stroke in patients who already 
have experienced an acute minor stroke or high- risk TIA 
and are carriers of CYP2C19 LOF alleles.
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